Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2000

View Archived Issues

BioChem Pharma makes solid progress during first quarter

Cel-Sci's herpes vaccine protective against HSV-1 in preclinical studies

Preliminary phase II results for Optin in AMD

IRB approves phase II pancreatic cancer trials of SafeScience's GBC-590

Idec updates Q1 developments, decides not to pursue SLE indication for IDEC-131

ImmunoGen product development for Q3 2000

Novel class of antiviral agents with improved properties

Patent issued to Isis covers antisense modulation of cREL expression

M. catarrhalis protein, its isolation and use in vaccines reported by Antex

Known antianginal agent claimed for use in retinal diseases by French researchers

Diagnostic imaging of NK1 receptors using Merck compounds

Preparation and use of new triterpenes as immunosuppressants described by Merck & Co.

New dopaminergic agents from Neurogen for neuropsychological disorders

Ares-Serono exercises license option to antiamyloid technology

Akorn obtains rights to AMD technology

Schering-Plough drops advanced-stage antibiotic upon final analysis of clinical data

Pyrimidine nucleosides with potent anti-VZV or anti-EBV activity discussed at recent conference

Genta's antisense drug active in advanced NHL

Avant Immunotherapeutics reports second-year rotavirus vaccine results

Novirio's new anti-HBV nucleosides among Antiviral Research conference highlights

Draximage files IND for Amiscan in U.S. and Canada

Study evaluates resveratrol effects in sputum from patients with COPD

European Commission gives go-ahead for Glaxo Wellcome-SmithKline Beecham merger

Viozan in the spotlight at ATS meeting

A promising development candidate for RSV disease: ViroPharma's VP-14637

GR-215864X: a safer glucocorticoid for asthma undergoes rapid inactivation in plasma

New Abbott compound at least as effective as ciclosporin, prednisolone in acute primate asthma model

New Viozan derivatives also enter clinical development for COPD at AstraZeneca

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...